Korean Journal of Food Science and Technology (한국식품과학회지)

Korean Society of Food Science and Technology (한국식품과학회)
권호 표지
DOI QR코드

DOI QR Code

Bioactive compounds in food for age-associated cognitive decline: A systematic review

인지기능 개선을 위한 식품유래 생리활성소재에 대한 체계적 문헌고찰

  • 강은영 (한양대학교 생활과학대학 식품영양학과) ;
  • 최봉교 (한양대학교 생활과학대학 식품영양학과) ;
  • 김현경 (한양대학교 생활과학대학 식품영양학과) ;
  • 고광웅 (한양대학교 생활과학대학 식품영양학과)
  • Received : 2021.02.01
  • Accepted : 2021.03.31
  • Published : 2021.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The rapid aging of society has led to a surge in cognitive dysfunction in the elderly. As there is limited evidence for the development of dementia in medicine, a shift in focus on prevention strategies using bioactive compounds in food is required. This systematic review evaluated the effects of various bioactive compounds on age-associated cognitive decline. The literature was searched for terms related to bioactive compounds in cognitive decline and article selection was limited to clinical randomized controlled trials for a single bioactive compound. We identified 21 studies that evaluated the strength of the evidence. ω-3 fatty acids and vitamin B presented a strong evidence level, whereas vitamin D and E, anserine/carnosine, and chromium were defined as having moderate levels of evidence. ω-3 fatty acids relieved cognitive decline and reduced amyloid β-related protein accumulation. Vitamin B decreased homocysteine levels, which is accompanied by alleviation of cognitive function. In conclusion, ω-3 and vitamin B have the potential to improve age-associated cognitive decline.

본 연구는 인지기능 개선에 도움이 되는 천연기능성소재를 선발하기 위해 체계적 문헌고찰을 실시하였다. 2020년 10월 06일 기준 문헌검색을 통해 16,184건을 수집하였고 선택 및 배제 기준에 따라 총 27건의 문헌을 선별하였다. 27건 중 ω-3 지방산 관련 논문 12건, 비타민 B군 관련 논문 8건, 비타민 D와 E 관련 논문 각각 1건이었으며, 안세린/카르노신, 베테인, 카페인, 크로뮴, 피소스티그민 관련 논문이 각각 1건이었다. 각 문헌의 비뚤림 위험 평가를 진행한 결과 ω-3 지방산 관련 논문 2건, 비타민 B군 관련 논문 1건, 베테인, 카페인, 피소스티그민 관련 논문의 비뚤림 위험이 '높음'으로 평가되었고, 비뚤림 위험이 높다고 평가된 6건의 논문들을 제외하고 근거수준평가 및 결과분석을 시행하였다. ω-3 지방산 관련 논문은 6-24개월동안 DHA 0.48-2.2 g, EPA 203-720 mg의 용량을 함께 또는 따로 중재하여 총 1,031명의 대상자 중 437명의 유의적인 효과를 확인하였다. 경도인지장애 환자를 대상으로 진행된 ω-3 지방산 논문에서는 인지기능영역(공간력, 기억력, 회상력, 언어력)과 인지기능 관련 바이오마커(Aβ-42, APP mRNA)를 개선시키는 등 치매개선에 긍정적인 효과를 나타냈다. 그러나 치매 환자를 대상으로 한 ω-3 지방산 연구에서는 인지기능평가에 대한 개선효과를 확인하기 어려웠다. 비타민 B 관련 논문은 6 또는 24개월 동안 엽산 400-800 ㎍, 비타민 B12 25-500 ㎍, 비타민 B6 20 mg의 용량을 함께 또는 따로 중재하여 총 1,180명의 대상자 중 530명에서 유의적인 효과를 확인하였다. 비타민 B군의 섭취는 치매 위험성과 관련된 혈중 호모시스테인 농도를 감소시켰으며, 혈중 ω-3 지방산의 농도와 높은 상관관계를 나타내는 것을 확인할 수 있었다. 그 외에 비타민 D와 E는 인지기능관련 바이오마커(Aβ-42, APP mRNA, PS1 mRNA)를 감소시키고 인지기능평가(WAIS-RC, ADAS-cog) 개선효과를 나타냈으며 안세린/카르노신은 치매척도검사를 개선하였고 크로뮴 섭취는 기억력 부분의 인지기능영역을 유의적으로 개선하였다. 그러나 ω-3 지방산과 비타민 B를 제외한 연구들은 선별된 문헌의 개수가 제한적이며, 개선 효과를 판단할 근거가 부족하였다. 중재 기간 및 용량에 따라 결과를 종합하면, ω-3 지방산은 6개월 이상 DHA 0.48-2.2 g, EPA 203-720 mg의 용량을 복합 또는 DHA 단독으로 중재했을 경우 인지기능 개선 효과를 확인할 수 있었으며, 엽산 400-800 ㎍, 비타민 B12 25-500 ㎍, 비타민 B6 20 mg의 용량을 복합 또는 엽산을 단독으로 6개월 이상 중재할 경우 혈중 호모시스테인 농도 감소와 인지능력개선을 확인할 수 있었다.

Keywords

Acknowledgement

본 연구는 '오뚜기 함태호 재단'의 연구비 지원을 받아 수행되었다.

References

  1. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, Van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal, LJ. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. Jama 300: 1774-1783 (2008) https://doi.org/10.1001/jama.300.15.1774
  2. Akhtar A, Dhaliwal J, Saroj P, Uniyal A, Bishnoi M, Sah SP. Chromium picolinate attenuates cognitive deficit in ICV-STZ rat paradigm of sporadic Alzheimer's-like dementia via targeting neuroinflammatory and IRS-1/PI3K/AKT/GSK-3β pathway. Inflammopharmacology 28: 385-400 (2020) https://doi.org/10.1007/s10787-019-00681-7
  3. Ali MM, Ghouri RG, Ans AH, Akbar A, Toheed A. Recommendations for anti-inflammatory treatments in Alzheimer's disease: a comprehensive review of the literature. Cureus 11: e4620 (2019)
  4. Artero S, Tierney MC, Touchon J, Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr. Scand. 107: 390-393 (2003) https://doi.org/10.1034/j.1600-0447.2003.00081.x
  5. Bo Y, Zhang X, Wang Y, You J, Cui H, Zhu Y, Pang W, Liu W, Jiang Y, Lu Q. The n-3 polyunsaturated fatty acids supplementation improved the cognitive function in the Chinese elderly with mild cognitive impairment: a double-blind randomized controlled trial. Nutrients 9: 54 (2017) https://doi.org/10.3390/nu9010054
  6. Buell JS, Dawson-Hughes B, Scott TM, Weiner DE, Dallal GE, Qui WQ, Bergethon P, Rosenberg IH, Folstein MF, Patz S, Bhadelia RA, Tucker KL. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 74: 18-26 (2010) https://doi.org/10.1212/WNL.0b013e3181beecb7
  7. Cederholm T. Fish consumption and omega-3 fatty acid supplementation for prevention or treatment of cognitive decline, dementia, or Alzheimer's disease in older adults-any news? Curr. Opin. Clin. Nutr. Metab. Care 20: 104-109 (2017) https://doi.org/10.1097/MCO.0000000000000350
  8. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int. J. Geriatr. Psychiatry 27: 592-600 (2012) https://doi.org/10.1002/gps.2758
  9. DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD, Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. Jama 300: 2253-2262 (2008) https://doi.org/10.1001/jama.2008.683
  10. Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol. Aging 22: 747-754 (2001) https://doi.org/10.1016/S0197-4580(01)00271-8
  11. Ding Q, Tanigawa K, Kaneko J, Totsuka M, Katakura Y, Imabayashi E, Matsuda H, Hisatsune T. Anserine/carnosine supplementation preserves blood flow in the prefrontal brain of elderly people carrying APOE ε4. Aging Dis. 9: 334 (2018) https://doi.org/10.14336/AD.2017.0809
  12. Dyall SC, Michael-Titus AT. Neurological benefits of omega-3 fatty acids. Neuromolecular Med. 10: 219-235 (2008) https://doi.org/10.1007/s12017-008-8036-z
  13. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, et al. Effect of vitamin E and memantine on functional decline in Alzheimer's disease: the TEAM-AD VA cooperative randomized trial. Jama 311: 33-44 (2014) https://doi.org/10.1001/jama.2013.282834
  14. Eckert GP, Lipka U, Muller WE. Omega-3 fatty acids in neurodegenerative disease: focus on mitochondria. Prostaglandins, Leukot. Essent. Fatty Acids 88: 105-114 (2013) https://doi.org/10.1016/j.plefa.2012.05.006
  15. Eriksdotter M, Vedin I, Falahati F, Freund-Levi Y, Hjorth E, FaxenIrving G, Wahlund LO, Schultzberg M, Basun H, Cederholm T, Palmblad J. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega-3 fatty acid supplementation: The OmegAD study. J. Alzheimers Dis. 48: 805-812 (2015) https://doi.org/10.3233/JAD-150102
  16. Feart C, Letenneur L, Helmer C, Samieri C, Schalch W, Etheve S, Delcourt C, Dartigues JF, Barberger-Gateau P. Plasma carotenoids are inversely associated with dementia risk in an elderly French cohort. J. Gerontol. A Biol. Sci. Med. Sci. 71: 683-688 (2016) https://doi.org/10.1093/gerona/glv135
  17. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 63: 1402-1408 (2006) https://doi.org/10.1001/archneur.63.10.1402
  18. Freund-Levi Y, Basun H, Cederholm T, Faxen-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jonhagen M. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int. J. Geriatr. Psychiatry 23: 161-169 (2008) https://doi.org/10.1002/gps.1857
  19. Freund-Levi Y, Vedin I, Hjorth E, Basun H, Faxen Irving G, Schultzberg M, Eriksdotter M, Palmblad J, Vessby B, Wahlund LO, Cederholm T, Basu S. Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. J. Alzheimer's Dis. 42: 823-831 (2014) https://doi.org/10.3233/JAD-132042
  20. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 13: 100-105 (2002) https://doi.org/10.1016/S1043-2760(01)00547-1
  21. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B. Mild cognitive impairment. The lancet 367: 1262-1270 (2006) https://doi.org/10.1016/S0140-6736(06)68542-5
  22. Green R, Allen LH, Bjorke-Monsen AL, Brito A, Gueant JL, Miller JW, Molloy AM, Nexo E, Stabler S, Toh BH, Ueland PM, Yajnik C. Vitamin B12 deficiency. Nat. Rev. Dis. Primers 3: 1-20 (2017)
  23. Gugliandolo A, Bramanti P, Mazzoz E. Role of vitamin E in the treatment of Alzheimer's disease: Evidence from animal models. Int. J. Mol. Sci. 18:2504 (2017) https://doi.org/10.3390/ijms18122504
  24. Haller S, Montandon ML, Rodriguez C, Moser D, Toma S, Hofmeister J, Sinanaj I, Lovblad KO, Giannakopoulos P. Acute caffeine administration effect on brain activation patterns in mild cognitive impairment. J. Alzheimers Dis. 41: 101-112 (2014) https://doi.org/10.3233/JAD-132360
  25. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams K, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41: 1088-1093 (2009) https://doi.org/10.1038/ng.440
  26. Hashimoto M, Kato S, Tanabe Y, Katakura M, Mamun AA, Ohno M, Hossain S, Onoda K, Yamaguchi S, Shido O. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing homes. Geriatr. Gerontol. Int. 17: 330-337 (2017)
  27. Henderson VW. Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J. Steroid Biochem. Mol. Biol. 142: 99-106 (2014) https://doi.org/10.1016/j.jsbmb.2013.05.010
  28. Hopperton KE, Trepanier MO, Giuliano V, Bazinet RP. Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-β 1-40 in mice. J. Neuroinflammation 13: 1-18 (2016) https://doi.org/10.1186/s12974-015-0467-5
  29. Isaac MGEKN, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev. 3 (2008)
  30. Jerneren F, Elshorbagy AK, Oulhaj A, Smith SM, Refsum H, Smith AD. Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. Am. J. Clin. Nutr. 102: 215-221 (2015) https://doi.org/10.3945/ajcn.114.103283
  31. Jia J, Hu J, Huo X, Miao R, Zhang Y, Ma F. Effects of vitamin D supplementation on cognitive function and blood Aβ-related bio-markers in older adults with Alzheimer's disease: a randomised, double-blind, placebo-controlled trial. J. Neurol. Neurosurg. Psychiatry Res. 90: 1347-1352 (2019)
  32. Kalueff AV, Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr. Opin. Clin. Nutr. Metab. Care 10: 12-19 (2007) https://doi.org/10.1097/MCO.0b013e328010ca18
  33. Karimi M, Vedin I, Freund Levi Y, Basun H, Faxen Irving G, Eriksdotter M, Wahlund LO, Schultzberg M, Hjorth E, Cederholm T, Palmblad J. DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study. Am. J. Clin. Nutr. 106: 1157-1165 (2017) https://doi.org/10.3945/ajcn.117.155648
  34. Killin LO, Starr JM, Shiue IJ, Russ TC. Environmental risk factors for dementia: a systematic review. BMC Geriatr. 16: 1-28 (2016) https://doi.org/10.1186/s12877-015-0167-0
  35. Krikorian R, Eliassen JC, Boespflug EL, Nash TA, Shidler MD. Improved cognitive-cerebral function in older adults with chromium supplementation. Nutr. Neurosci. 13: 116-122 (2010) https://doi.org/10.1179/147683010X12611460764084
  36. Kryscio RJ, Abner EL, Caban-Holt A, Lovell, M, Goodman P, Darke AK, Yee M, Crowley J, Schmitt FA. Association of antioxidant supplement use and dementia in the prevention of Alzheimer's disease by vitamin E and selenium trial (PREADViSE). JAMA Neurol. 74: 567-573 (2017) https://doi.org/10.1001/jamaneurol.2016.5778
  37. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41: 1094-1099 (2009) https://doi.org/10.1038/ng.439
  38. Lee DW, Seong SJ. Korean national dementia plans: from 1st to 3rd. J. Korean Med. Assoc. 61: 298-303 (2018) https://doi.org/10.5124/jkma.2018.61.5.298
  39. Lee LK, Shahar S, Chin AV, Yusoff NAM. Docosahexaenoic acidconcentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial. Psychopharmacology 225: 605-612 (2013) https://doi.org/10.1007/s00213-012-2848-0
  40. Ma F, Li Q, Zhou X, Zhao J, Song A, Li W, Liu H, Xu W, Huang G. Effects of folic acid supplementation on cognitive function and Aβ-related biomarkers in mild cognitive impairment: a randomized controlled trial. Eur. J. Nutr. 58: 345-356 (2019a) https://doi.org/10.1007/s00394-017-1598-5
  41. Ma F, Zhou X, Li Q, Zhao J, Song A, An P, Du Y, Xu W, Huang G. Effects of folic acid and vitamin B12, alone and in combination on cognitive function and inflammatory factors in the elderly with mild cognitive impairment: A single-blind experimental design. Curr. Alzheimer Res. 16: 622-632 (2019b) https://doi.org/10.2174/1567205016666190725144629
  42. Macready AL, Kennedy OB, Ellis JA, Williams CM, Spencer JP, Butler LT. Flavonoids and cognitive function: a review of human randomized controlled trial studies and recommendations for future studies. Genes Nutr. 4: 227-242 (2009) https://doi.org/10.1007/s12263-009-0135-4
  43. Masuoka N, Yoshimine C, Hori M, Tanaka M, Asada T, Abe K, Hisatsune T. Effects of anserine/carnosine supplementation on mild cognitive impairment with APOE ε4. Nutrients 11: 1626 (2019) https://doi.org/10.3390/nu11071626
  44. Moll R, Davis B. Iron, vitamin B12 and folate. Medicine 45: 198-203 (2017) https://doi.org/10.1016/j.mpmed.2017.01.007
  45. Morello M, Landel V, Lacassagne E, Baranger K, Annweiler C, Feron F, Millet P. Vitamin D improves neurogenesis and cognition in a mouse model of Alzheimer's disease. Mol. Neurobiol. 55: 6463-6479 (2018) https://doi.org/10.1007/s12035-017-0839-1
  46. Mucke L. Alzheimer's disease. Nature 461: 895-897 (2009) https://doi.org/10.1038/461895a
  47. National Institutes of Health. How is Alzheimer's disease treated? Available from: https://www.nia.nih.gov/health/how-alzheimersdisease-treated. Accessed Jan. 25, 2021
  48. National Institutes of Health. What is mild cognitive impairment? Available from: https://www.nia.nih.gov/health/what-mild-cognitive-impairment. Accessed Jan. 25, 2021
  49. Oulhaj A, Jerneren F, Refsum H, Smith AD, de Jager CA. Omega-3 fatty acid status enhances the prevention of cognitive decline by B vitamins in mild cognitive impairment. J. Alzheimers Dis. 50: 547-557 (2016) https://doi.org/10.3233/JAD-150777
  50. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352: 2379-2388 (2005) https://doi.org/10.1056/NEJMoa050151
  51. Petersen RC. Mild cognitive impairment. N. Engl. J. Med. 364: 2227-2234 (2011) https://doi.org/10.1056/NEJMcp0910237
  52. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR, Weiner M, Shinto L, Aisen PS. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. Jama 304: 1903-1911 (2010) https://doi.org/10.1001/jama.2010.1510
  53. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, Johnston C, Engbaek F, Schneede J, McPartlin C, Scott JM. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin. Chem. 50: 3-32 (2004) https://doi.org/10.1373/clinchem.2003.021634
  54. Riggs KM, Spiro 3rd A, Tucker K, Rush D. Relations of vitamin B12, vitamin B6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am. J. Clin. Nutr. 63: 306-314 (1996) https://doi.org/10.1093/ajcn/63.3.306
  55. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, et al. The neuronal sortilinrelated receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39: 168-177 (2007) https://doi.org/10.1038/ng1943
  56. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N. Engl. J. Med. 336: 1216-1222 (1997) https://doi.org/10.1056/NEJM199704243361704
  57. Scholey AB, Camfield DA, Hughes ME, Woods W, Stough CKK, White DJ, Gondalia SV, Frederiksen PD. A randomized controlled trial investigating the neurocognitive effects of Lacprodan® PL-20, a phospholipid-rich milk protein concentrate, in elderly participants with age-associated memory impairment: The Phospholipid Intervention for Cognitive Ageing Reversal (PLICAR): study protocol for a randomized controlled trial. Trials 14: 1-15 (2013) https://doi.org/10.1186/1745-6215-14-1
  58. Schultz BG, Patten DK, Berlau DJ. The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms. Transl. Neurodegener. 7: 1-11 (2018) https://doi.org/10.1186/s40035-018-0106-z
  59. Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PloS one 5: e12244 (2010) https://doi.org/10.1371/journal.pone.0012244
  60. Statistics Korea. 2020 Elderly statistics. Available from: http://kostat.go.kr/portal/korea/kor_nw/1/1/index.board?bmode=read&aSeq=385322. Accessed Jan. 25, 2021
  61. Sun J, Wen S, Zhou J, Ding S. Association between malnutrition and hyperhomocysteine in Alzheimer's disease patients and diet intervention of betaine. J. Clin. Lab. Anal. 31: e22090 (2017) https://doi.org/10.1002/jcla.22090
  62. Szczesniak D, Budzen S, Kopec W, Rymaszewska J. Anserine and carnosine supplementation in the elderly: Effects on cognitive functioning and physical capacity. Arch. Gerontol. Geriat. 59: 485-490 (2014) https://doi.org/10.1016/j.archger.2014.04.008
  63. Thal LJ, Ferguson JM, Mintzer JE, Raskin A, Targum SD. A 24- week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 52: 1146-1146 (1999) https://doi.org/10.1212/WNL.52.6.1146
  64. van Uffelen JG, Chinapaw MJ, van Mechelen W, Hopman-Rock M. Walking or vitamin B for cognition in older adults with mild cognitive impairment? A randomised controlled trial. Br. J. Sports Med. 42: 344-351 (2008) https://doi.org/10.1136/bjsm.2007.044735
  65. Vedin I, Cederholm T, Freund-Levi Y, Basun H, Garlind A, Faxen Irving G, Eriksdotter-Jonhagen M, Wahlund LO, Dahlman I, Palmblad J. Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PloS one 7: e35425 (2012) https://doi.org/10.1371/journal.pone.0035425
  66. Wilson MP, Plecko B, Mills PB, Clayton PT. Disorders affecting vitamin B6 metabolism. J. Inherit. Metab. Dis. 42: 629-646 (2019) https://doi.org/10.1002/jimd.12060
  67. World Health Organization. Dementia. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia. Accessed Jan. 25, 2021
  68. Yokota T, lgarashi K, Uchihara T, Jishage KI, Tomita H, Inaba A, Li Y, Arita M, Suzuki H, Mizusawa H, Arai H. Delayed-onset ataxia in mice lacking α-tocopherol transfer protein: model for neuronal degeneration caused by chromic oxidative stress. Proc. Natl. Acad. Sci. 98: 15185-15190 (2001) https://doi.org/10.1073/pnas.261456098
  69. Zhang YP, Lou Y, Hu J, Miao R, Ma F. DHA supplementation improves cognitive function via enhancing Aβ-mediated autophagy in Chinese elderly with mild cognitive impairment: a randomised placebo-controlled trial. J. Neurol. Neurosurg. Psychiatry Res. 89: 382-388 (2018) https://doi.org/10.1136/jnnp-2017-316176
  70. Zhang YP, Miao R, Li Q, Wu T, Ma F. Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: A 12-month randomized, double-blind, placebo-controlled trial. J. Alzheimers Dis. 55: 497-507 (2017) https://doi.org/10.3233/JAD-160439